Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma

Kelly, Ronan J; Chung, Ki; Gu, Yu; Steele, Keith E; Rebelatto, Marlon C; Robbins, Paul B; Tavakkoli, Fatemeh; Karakunnel, Joyson J; Lai, Dominic W; Almhanna, Khaldoun

doi:10.1186/2051-1426-3-S2-P157

Article metrics
Last updated: Sat, 20 Apr 2024 10:12:33 Z

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma

Access & Citations

1010

Article Accesses
0

Web of Science
10

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.